BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 17 November, 2008, at
12.15
Notification according to Chapter 2, Section 10 of the Finnish
Securities Market Act
Biotie Therapies Corp. ("Company") has gained knowledge of the
following changes in holdings in accordance with Chapter 2, Section 9
of the Finnish Securities Markets Act. The changes in holdings in the
shares of the Company concern Pequot Healthcare Fund, L.P., Pequot
Healthcare Offshore Fund, Inc., Premium Series PCC Limited - Cell 32,
Pequot Diversified Master Fund, Ltd., Pequot Healthcare Institutional
Fund, L.P. and Pequot Healthcare Emerging Markets Fund, Ltd.
(together "Pequot funds"), elbion NV, Sitra, the Finnish Innovation
Fund, Finnish Industry Investment Ltd as well as Mr. Juha Jouhki and
the companies under his control, Thominvest Oy and Dreadnought
Finance Oy.
The changes in holdings of the abovementioned shareholders have taken
place due to a share issue by Biotie Therapies Corp. The share issue
was a part of the transaction executed on 14 November 2008 in which
Biotie Therapies Corp. acquired the share capital of elbion GmbH. The
details of the transaction have been disclosed by a stock exchange
release on 24 October 2008.
Of the abovementioned shareholders, new shares in the share issue
were directed only to elbion NV.
The changes in holdings in accordance with Chapter 2, Section 9 of
the Finnish Securities Markets Act of which the Company has gained
knowledge are described below.
+-------------------------------------------------------------------+
| Name of the | Shares | Holdings % | Holdings | Change |
| shareholder | | before | % | % units |
| | | issues | after | |
| | | | issues | |
|--------------------+------------+------------+----------+---------|
| elbion NV | 46,802,967 | 0,0 | 32,43 | 32,43 |
|--------------------+------------+------------+----------+---------|
| Sitra, the Finnish | | | | 6.06 |
| Innovation Fund | 14,585,350 | 16.17 | 10.11 | |
|--------------------+------------+------------+----------+---------|
| Pequot Healthcare | 7,244,966 | 8.03 | 5.02 | 3.01 |
| Fund, L.P. | | | | |
|--------------------+------------+------------+----------+---------|
| Pequot Healthcare | 6,387,783 | 7.08 | 4.43 | 2.65 |
| Offshore Fund, Inc | | | | |
|--------------------+------------+------------+----------+---------|
| Pequot Healthcare | 3,571,637 | 3.96 | 2.47 | 1.48 |
| Emerging Markets | | | | |
| Fund, Ltd. | | | | |
|--------------------+------------+------------+----------+---------|
| Pequot Healthcare | 2,254,305 | 2.50 | 1.56 | 0.94 |
| Institutional | | | | |
| Fund, LP | | | | |
|--------------------+------------+------------+----------+---------|
| Premium Series | 2,111,387 | 2.34 | 1.46 | 0.88 |
| PCC, Limited-Cell | | | | |
| 32 | | | | |
|--------------------+------------+------------+----------+---------|
| Pequot Diversified | 1,314,100 | 1.46 | 0.91 | 0.55 |
| Master Fund, Ltd. | | | | |
|--------------------+------------+------------+----------+---------|
| Pequot funds in | 22,884,178 | 25.37 | 15.86 | 9.51 |
| total | | | | |
|--------------------+------------+------------+----------+---------|
| Finnish Industry | | | | 2,81 |
| Investment Ltd | 6,778,592 | 7,51 | 4,70 | |
|--------------------+------------+------------+----------+---------|
| Thominvest Oy | 2,937,900 | 3,26 | 2,04 | 1,22 |
|--------------------+------------+------------+----------+---------|
| Dreadnought | 2,098,416 | 2,33 | 1,45 | 0,88 |
| Finance Oy | | | | |
|--------------------+------------+------------+----------+---------|
| Jouhki Juha Heikki | 1,501,356 | 1,66 | 1,04 | 0,62 |
| Tapio | | | | |
|--------------------+------------+------------+----------+---------|
| Juha Jouhki and | 6,537,672 | 7,25 | 4,53 | 2,72 |
| companies under | | | | |
| his control in | | | | |
| total | | | | |
+-------------------------------------------------------------------+
The share capital of Biotie Therapies Corp. constitutes 90 211 860
shares in the aggregate and the number of voting rights attached to
the shares amounts to 90 211 860. After the new shares issued in the
share issue resolved on 14 November 2008 shall be registered with the
Trade Register on 14 November 2008, the number of shares and voted in
the Company shall be 144 320 560.
Turku, on 17 November, 2008
Timo Veromaa
President and CEO
For further information, please contact:
Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: timo.veromaa@biotie.com
www.biotie.com
DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
| Source: Biotie Therapies